about
Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotypeEDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families.EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C > T mutation.Challenges for synthesising data in a network of registries for systemic psoriasis therapies.The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.Hair shaft structures in EDAR induced ectodermal dysplasia.Sustained PASI, DLQI and EQ-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement.Health-care delay in malignant melanoma: various pathways to diagnosis and treatment.Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients.Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics.How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden.Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent.Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).What can we learn from 'dropouts' in clinical trials?Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study.Physical activity and lifestyle improvement in the management of psoriasis.Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective lociAssociation between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasisType I and type II psoriasis show a similar usage of T-cell receptor variable regionsPolymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individualsPromoter polymorphism at -238 of the tumor necrosis factor alpha gene is not associated with early onset psoriasis when tested by the transmission disequilibrium testSurvival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokinesPsoriasis therapy in real life: the need for registriesPsoReg--the Swedish registry for systemic psoriasis treatment. The registry's design and objectivesSwitching biologicals: switching TNFalpha antagonists in psoriasis treatmentMalignant melanoma: gender patterns in care seeking for suspect marksResource use in patients with psoriasis after the introduction of biologics in SwedenAnti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and SwedenComplete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goalsHealth-related quality of life in patients with melanoma - characterization of a Swedish cohort[Register studies measure the effectiveness of drugs in clinical practice. The example PsoReg - redistribution of systemic treatment can increase the efficiency]
P50
Q28269330-C51CCB8D-E99E-4617-8EFB-F5B87F1957B4Q33264588-5FAA2398-7E61-41E7-AE79-EF6CD8761ED2Q33678967-A022B798-795E-4012-BB38-A06EB8C1F1CFQ34296816-C4A8A416-2B92-438B-B4E2-630F701CB6DCQ34730794-EAE1BF13-1889-403C-B0AF-429234A53FE1Q35763910-94FE22D3-9076-4661-89C8-660B1E347388Q36413344-7EEA517B-A2AC-4A8B-BCE2-9D4F3F7330D4Q37396896-4F0FED56-1661-4449-83D2-104C70A49C14Q37553452-82D0D62B-FA9B-46BE-B230-355598E107FBQ37601452-F88743D9-AAFB-4BDB-8FAD-C440DF646F41Q38411063-9AD6F153-64D5-43E9-BD09-4AF2D0ADBE1BQ38654766-81BD5AF4-B836-4CEF-BD99-87A2A3D4E912Q38993275-F969BCCD-50E6-4BDE-AFBC-CBDCFF2A1662Q40209526-694FCBA4-2FA8-4ADE-8B0E-56E64D8B1643Q40989242-B11B861E-1FA6-4E49-BC36-AF3D569C3674Q41344463-3B6A5E30-E0F8-4A73-B9AE-9AFD5A368F69Q43960004-4617CB69-625A-437F-9C4D-FFD013749223Q47883565-B35BE22E-32A7-4BFB-A386-D21CF3719A95Q48073724-8A6F7D1C-6C8C-49D8-97B7-47D80075A09EQ50020802-40CBCFDE-556B-4703-B477-EF381BFD6965Q53007194-16D8BECA-A20D-4E80-B9DD-6EF55CB98050Q54024317-85E77415-4B8C-42D9-BC0E-504AABEBC1D0Q57990849-F6312C38-883C-4152-9A43-D3BD63699991Q61990707-FE24280B-CE3F-42B3-BC8D-E72DC937DFABQ67905113-FEDDA6A0-F83B-4174-A7B1-26E41B93A7A9Q72070434-14A0C5CD-9A19-42B0-B96B-A18E75BEFB2DQ77319176-DF078D6E-DB33-4D46-B854-8B6BD4DE7128Q78224795-7FFD3B7C-D738-4324-86D2-511CB5CDC343Q79394118-91A52F15-005B-4AB7-8BA7-BA4CD13F623CQ79887578-6A79CF24-5799-48D4-B8AE-DA775703FBEBQ80577251-654E15FB-CAEE-49FE-84A8-987FB6D3CEF5Q84581597-6495FFF3-DC56-4DFB-8B58-04A5159FA55EQ87858188-FA83E5C3-BDFB-46E0-A3DE-592B2F13083EQ89535395-0B20D397-867D-4066-8D0B-7FDC271CBFD3Q92039424-9488F55C-122F-4357-AC88-D8AFCB5BB31CQ93123194-F5054B42-DC0E-454B-BF2D-8FB0A54A9FD9Q95485980-D30BCE5E-F2E3-4F33-9FC6-D2C4F7A4BF58
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marcus Schmitt-Egenolf
@ast
Marcus Schmitt-Egenolf
@en
Marcus Schmitt-Egenolf
@es
Marcus Schmitt-Egenolf
@nl
Marcus Schmitt-Egenolf
@sl
type
label
Marcus Schmitt-Egenolf
@ast
Marcus Schmitt-Egenolf
@en
Marcus Schmitt-Egenolf
@es
Marcus Schmitt-Egenolf
@nl
Marcus Schmitt-Egenolf
@sl
prefLabel
Marcus Schmitt-Egenolf
@ast
Marcus Schmitt-Egenolf
@en
Marcus Schmitt-Egenolf
@es
Marcus Schmitt-Egenolf
@nl
Marcus Schmitt-Egenolf
@sl
P106
P108
P1153
6602077311
P31
P496
0000-0002-3858-8474